[Ip-health] ITPC Activists Occupy Novartis: Demand Access to Medicine Over Corporate Profit

Gregg Gonsalves gregg.gonsalves at gmail.com
Wed Feb 22 11:24:58 PST 2012

This is amazing!!!!

On Wed, Feb 22, 2012 at 2:11 PM, Matthew Kavanagh <matthew at healthgap.org>wrote:

> **
> Wednesday, 22 February 2012
> *For Immediate Release*
> *Activists Occupy Novartis: Demand Access to Medicine Over Corporate
> Profit** *
> *In NY, DC, and Boston, activists take over Novartis offices warning that
> pharma giant Novartis’ lawsuit in India could deny millions around the
> world to lifesaving medicines.*
> *Contact: *Matthew Kavanagh, Health GAP, 202-486-2488,
> matthew at healthgap.org; Darshali Vyas, Student Global AIDS Campaign,
> 859-420-6498, davyas at college.harvard.edu
> AIDS activists, students, and community groups “OCCUPIED” the offices of
> pharma giant Novartis today in three U.S. cities on the eve of the Swiss
> pharmaceutical company’s annual shareholders meeting in Switzerland.  The
> effort was part of a global day of action drawing attention to the
> company’s lawsuit against cancer patients and the government of India,
> aiming to reinterpret India’s patent standards to block access to
> life-saving generic medicines.
> In 2006, Novartis sued the Indian government after its request for a
> patent on its blockbuster cancer drug Gleevec was denied. The Novartis
> version of the drug costs roughly ten times the cost of the high-quality
> generics on the market and the company is trying to stop production of
> those versions.  Prior to 2005, India did not grant patents on medicines
> at all – a policy that fostered generic production of essential medicines
> then shipped to poor countries around the world. After a World Trade
> Organization agreement forced India to start granting patents in 2005,
> India created Section 3(d) of its patent law that requires pharmaceutical
> companies to demonstrate that changes to an existing substance actually
> shows increased efficacy for patients before a new patent is
> granted—preventing frivolous patents. Novartis was unable to show that its
> tweaks to the basic compound in Gleevec had resulted in improved efficacy
> in treating cancer.
> “Without this protective provision in place, patents will be granted
> indiscriminately on trivial changes to existing medicines, thereby
> preventing generic production and allowing drug companies to charge high
> prices,” explained Brook Baker, policy analyst for Health GAP (Global
> Access Project).
> India has historically proved vital in the global fight against
> AIDS—producing the vast majority of high quality, affordable drugs used in
> Africa and throughout the world.
> “Novartis’s shortsighted corporate greed could have disastrous long-term
> consequences for nations reliant on generic medicines. India supplies 80%
> of AIDS medicines in the developing world as well as good quality generic
> equivalents for many other health needs.  Poor patients will continue to
> need access to new, improved, and affordable medicines instead of having
> them blocked by successive patent monopolies,” said Darshali Vyas, from
> Harvard College and member of the Student Global AIDS Campaign.
> Since Novartis initiated action against the Indian government, protests
> have been held around the world. On Wednesday, demonstrators in New York,
> Washington, and Boston stood in solidarity with actions in India,
> Switzerland, and other regions. “We’re here to try to ensure that India
> remains the pharmacy of the developing world,” said Katrina Ciraldo, Boston
> University medical student and member of Occupy Boston’s Health Justice
> group.****
> ###
>  __._,_.___
>   Reply to sender<matthewkavanaghx at gmail.com?subject=Re%3A%20Activists%20Occupy%20Novartis%3A%20Demand%20Access%20to%20Medicine%20Over%20Corporate%20Profit>| Reply
> to group<internationaltreatmentpreparedness at yahoogroups.com?subject=Re%3A%20Activists%20Occupy%20Novartis%3A%20Demand%20Access%20to%20Medicine%20Over%20Corporate%20Profit>| Reply
> via web post<http://groups.yahoo.com/group/internationaltreatmentpreparedness/post;_ylc=X3oDMTJxdG1jN20zBF9TAzk3MzU5NzE0BGdycElkAzk3MjcyMjEEZ3Jwc3BJZAMxNzA1MDYxNTkwBG1zZ0lkAzIxODQ4BHNlYwNmdHIEc2xrA3JwbHkEc3RpbWUDMTMyOTkzODM0OA--?act=reply&messageNum=21848>| Start
> a New Topic<http://groups.yahoo.com/group/internationaltreatmentpreparedness/post;_ylc=X3oDMTJlMTcxcGx0BF9TAzk3MzU5NzE0BGdycElkAzk3MjcyMjEEZ3Jwc3BJZAMxNzA1MDYxNTkwBHNlYwNmdHIEc2xrA250cGMEc3RpbWUDMTMyOTkzODM0OA-->
> Messages in this topic<http://groups.yahoo.com/group/internationaltreatmentpreparedness/message/21848;_ylc=X3oDMTM2bDQ4bGFsBF9TAzk3MzU5NzE0BGdycElkAzk3MjcyMjEEZ3Jwc3BJZAMxNzA1MDYxNTkwBG1zZ0lkAzIxODQ4BHNlYwNmdHIEc2xrA3Z0cGMEc3RpbWUDMTMyOTkzODM0OAR0cGNJZAMyMTg0OA-->(
> 1)
>  Recent Activity:
>    - New Members<http://groups.yahoo.com/group/internationaltreatmentpreparedness/members;_ylc=X3oDMTJmZTRkczBhBF9TAzk3MzU5NzE0BGdycElkAzk3MjcyMjEEZ3Jwc3BJZAMxNzA1MDYxNTkwBHNlYwN2dGwEc2xrA3ZtYnJzBHN0aW1lAzEzMjk5MzgzNDg-?o=6>
>    1
>  Visit Your Group<http://groups.yahoo.com/group/internationaltreatmentpreparedness;_ylc=X3oDMTJlaHVqMzhsBF9TAzk3MzU5NzE0BGdycElkAzk3MjcyMjEEZ3Jwc3BJZAMxNzA1MDYxNTkwBHNlYwN2dGwEc2xrA3ZnaHAEc3RpbWUDMTMyOTkzODM0OA-->
>  [image: Yahoo! Groups]<http://groups.yahoo.com/;_ylc=X3oDMTJka2RzOTM0BF9TAzk3NDc2NTkwBGdycElkAzk3MjcyMjEEZ3Jwc3BJZAMxNzA1MDYxNTkwBHNlYwNmdHIEc2xrA2dmcARzdGltZQMxMzI5OTM4MzQ4>
> Switch to: Text-Only<internationaltreatmentpreparedness-traditional at yahoogroups.com?subject=Change+Delivery+Format:+Traditional>,
> Daily Digest<internationaltreatmentpreparedness-digest at yahoogroups.com?subject=Email+Delivery:+Digest>•
> Unsubscribe<internationaltreatmentpreparedness-unsubscribe at yahoogroups.com?subject=Unsubscribe>• Terms
> of Use <http://docs.yahoo.com/info/terms/>
>    .
> __,_._,___

Gregg Gonsalves
100 York Street
University Towers, 10-D
New Haven, CT 06511
Email: gregg.gonsalves at gmail.com or gregg.gonsalves at yale.edu
Mobile: +1-203-606-9149

More information about the Ip-health mailing list